数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
J. Rodney Varner Chairman,Chief Executive Officer and Secretary 64 115.26万美元 未持股 2021-04-30
William R. Wilson, Jr. Director 71 14.72万美元 未持股 2021-04-30
Jose Antonio Moreno Toscano Director 48 15.16万美元 未持股 2021-04-30
Brent M. Longnecker Director 64 15.16万美元 未持股 2021-04-30

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
J. Rodney Varner Chairman,Chief Executive Officer and Secretary 64 115.26万美元 未持股 2021-04-30
Ryan M. Confer Chief Financial Officer 39 127.02万美元 未持股 2021-04-30
Michael T. Redman Executive Vice President and Chief Operating Officer 66 未披露 未持股 2021-04-30
Catherine M. Vaczy Executive Vice President and Chief Strategy Officer 59 77.39万美元 未持股 2021-04-30

董事简历

中英对照 |  中文 |  英文
J. Rodney Varner

J.Rodney Varner是Genprex的联合创始人,自2012年8月以来一直担任我们的首席执行官兼秘书,以及董事会成员和董事会主席。Varner先生还担任我们的总裁,直到2018年4月10日。Varner先生从1991年开始担任律师事务所Wilson&Varner,LLP的合伙人。Varner先生曾在董事会或高级管理层代表营利性和非营利公司处理各种合同,业务,税收和证券事务,包括技术转让,许可,合作和研究协议,临床试验合同,制药和生物制剂制造和工艺开发合同,州和联邦赠款,包括NIH和SBA赠款,公司治理和信托问题以及房地产事务。Varner先生曾担任公司组建,并购,资本筹集,其他业务交易,商业秘密和其他知识产权保护,房地产和商业诉讼的法律顾问。Varner先生是德克萨斯州律师协会(State Bar of Texas)的成员,并已获准在美国第五巡回上诉法院和美国税务法院(United States Tax Court)执业。Varner先生在德州农工大学(Texas A&M University)以优异的成绩获得工商管理学士学位,并在德克萨斯大学法学院(University of Texas School of Law)获得法学博士学位。


J. Rodney Varner, is a co-founder of Genprex and has served as our Chief Executive Officer and Secretary, and as a member of our Board and as Chairman of our Board since August 2012. Mr. Varner also served as our President from August 2012 until April 10 2018. Mr. Varner was again appointed President on August 10 2020 and currently serves as our President. Mr. Varner has served as a partner of the law firm Wilson & Varner, LLP, since 1991. Mr. Varner has more than 35 years of legal experience with large and small law firms, and as outside general counsel of a Nasdaq listed company. Mr. Varner has represented for-profit and non-profit companies at the board or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers, licensing, collaboration and research agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues, and real estate matters. Mr. Varner served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. Mr. Varner is a member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for the Fifth Circuit and the United States Tax Court. Mr. Varner holds a Bachelor of Business Administration degree, with high honors, from Texas A&M University and a JD degree from The University of Texas School of Law.
J.Rodney Varner是Genprex的联合创始人,自2012年8月以来一直担任我们的首席执行官兼秘书,以及董事会成员和董事会主席。Varner先生还担任我们的总裁,直到2018年4月10日。Varner先生从1991年开始担任律师事务所Wilson&Varner,LLP的合伙人。Varner先生曾在董事会或高级管理层代表营利性和非营利公司处理各种合同,业务,税收和证券事务,包括技术转让,许可,合作和研究协议,临床试验合同,制药和生物制剂制造和工艺开发合同,州和联邦赠款,包括NIH和SBA赠款,公司治理和信托问题以及房地产事务。Varner先生曾担任公司组建,并购,资本筹集,其他业务交易,商业秘密和其他知识产权保护,房地产和商业诉讼的法律顾问。Varner先生是德克萨斯州律师协会(State Bar of Texas)的成员,并已获准在美国第五巡回上诉法院和美国税务法院(United States Tax Court)执业。Varner先生在德州农工大学(Texas A&M University)以优异的成绩获得工商管理学士学位,并在德克萨斯大学法学院(University of Texas School of Law)获得法学博士学位。
J. Rodney Varner, is a co-founder of Genprex and has served as our Chief Executive Officer and Secretary, and as a member of our Board and as Chairman of our Board since August 2012. Mr. Varner also served as our President from August 2012 until April 10 2018. Mr. Varner was again appointed President on August 10 2020 and currently serves as our President. Mr. Varner has served as a partner of the law firm Wilson & Varner, LLP, since 1991. Mr. Varner has more than 35 years of legal experience with large and small law firms, and as outside general counsel of a Nasdaq listed company. Mr. Varner has represented for-profit and non-profit companies at the board or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers, licensing, collaboration and research agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues, and real estate matters. Mr. Varner served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. Mr. Varner is a member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for the Fifth Circuit and the United States Tax Court. Mr. Varner holds a Bachelor of Business Administration degree, with high honors, from Texas A&M University and a JD degree from The University of Texas School of Law.
William R. Wilson, Jr.

William R. Wilson,Jr.自2020年3月18日以来一直担任我们的董事会成员。2006年1月以来,他曾一直担任Wilson Land&Cattle公司(投资公司)的主席、总裁兼首席执行官。Wilson先生在医疗保健监管、生物技术、临床试验管理、养老院许可和监管、医师认证、证券、公司治理、合同和其他法律事务方面拥有超过40年的法律经验。Wilson先生是德克萨斯州律师协会的成员,并已被允许在美国德克萨斯州西区地方法院执业。Wilson先生曾担任德克萨斯州特拉维斯县第250地区法院的法官,在那里他主持民事诉讼,并担任德克萨斯州达拉斯县的助理地区检察官。Wilson先生拥有范德比尔特大学的理学学士学位和南卫理公会大学的法学博士学位。


William R. Wilson, Jr., has served as a member of our Board since March 18 2020. Since January 2006 he has served as Chairman, President and Chief Executive Officer of Wilson Land & Cattle Co., an investment company. Mr. Wilson has more than 40 years of legal experience in health care regulation, biotechnology, clinical trial management, nursing home licensing and regulation, physician accreditation, securities, corporate governance, contractual and other legal matters. Mr. Wilson is a member of the State Bar of Texas and has been admitted to practice before the United States District Court for the Western District of Texas. Mr. Wilson previously served as Judge of the 250th District Court of Travis County, Texas, where he presided over civil litigation, and as Assistant District Attorney for Dallas County, Texas. Mr. Wilson holds a Bachelor of Science degree from Vanderbilt University and a JD degree from Southern Methodist University.
William R. Wilson,Jr.自2020年3月18日以来一直担任我们的董事会成员。2006年1月以来,他曾一直担任Wilson Land&Cattle公司(投资公司)的主席、总裁兼首席执行官。Wilson先生在医疗保健监管、生物技术、临床试验管理、养老院许可和监管、医师认证、证券、公司治理、合同和其他法律事务方面拥有超过40年的法律经验。Wilson先生是德克萨斯州律师协会的成员,并已被允许在美国德克萨斯州西区地方法院执业。Wilson先生曾担任德克萨斯州特拉维斯县第250地区法院的法官,在那里他主持民事诉讼,并担任德克萨斯州达拉斯县的助理地区检察官。Wilson先生拥有范德比尔特大学的理学学士学位和南卫理公会大学的法学博士学位。
William R. Wilson, Jr., has served as a member of our Board since March 18 2020. Since January 2006 he has served as Chairman, President and Chief Executive Officer of Wilson Land & Cattle Co., an investment company. Mr. Wilson has more than 40 years of legal experience in health care regulation, biotechnology, clinical trial management, nursing home licensing and regulation, physician accreditation, securities, corporate governance, contractual and other legal matters. Mr. Wilson is a member of the State Bar of Texas and has been admitted to practice before the United States District Court for the Western District of Texas. Mr. Wilson previously served as Judge of the 250th District Court of Travis County, Texas, where he presided over civil litigation, and as Assistant District Attorney for Dallas County, Texas. Mr. Wilson holds a Bachelor of Science degree from Vanderbilt University and a JD degree from Southern Methodist University.
Jose Antonio Moreno Toscano

Jose AntonioMoreno Toscano自2020年3月18日起担任我们的董事会成员。自2018年4月以来,Moreno Toscano先生一直担任LFB USA Inc.的首席执行官,LFB USA Inc.是LFB Group的美国子公司,LFB Group是一家全球综合生物制药公司,致力于通过重组,血浆衍生和细胞治疗技术开发创新产品。从2017年7月至2018年3月,Moreno Toscano先生担任安全港合规和临床服务总裁,这是一家综合医疗服务提供商,致力于在初级保健办公室提供特种药品和辅助服务。从2016年7月至2018年9月,他还担任董事会成员。从2016年3月至2017年3月,Moreno Toscano先生担任Kompan Inc.的美洲首席执行官,该公司是Kompan A/S的美国子公司,是游乐场设备的全球领导者。从2006年3月到2016年3月,Moreno Toscano先生担任ALK-Abello Inc.的总裁,该公司是ALK-Abello A/S的美国子公司,该公司是一家制药公司,是过敏免疫疗法的全球领导者。任职ALK-Abello公司之前,他曾担任APplus A/S公司(汽车检测服务的市场领导者)的首席财务官,也曾担任Christian Hansen Holding A/S公司(制药制造和食品、饮料天然成分的生产商的全球领导者)的多种职务,膳食补充剂和农业产业。Moreno Toscano先生拥有西班牙穆尔西亚大学的法学硕士学位和巴黎国立庞茨和肖斯学院的国际金融和战略工商管理硕士学位。Moreno Toscano先生拥有全国公司董事协会NACD董事证书。


Jose Antonio Moreno Toscano, has served as a member of our Board since March 18 2020. Since April 2018 Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc., the US subsidiary of LFB Group, a global integrated biopharmaceutical company dedicated to developing innovative products through recombinant, plasma derived and cell therapy technology. From July 2017 to March 2018 Mr. Moreno Toscano served as President of Safe Harbor Compliance and Clinical Services, an integrated health care services provider dedicated to providing specialty pharmaceuticals and ancillary services in primary care offices. From July 2016 to September 2018 he also served as a member of the board of directors. From March 2016 to March 2017 Mr. Moreno Toscano served as CEO, Americas, for Kompan Inc., a US subsidiary of Kompan A/S, a world leader in playground equipment. From March 2006 to March 2016 Mr. Moreno Toscano served as President of ALK-Abello Inc., a US subsidiary of ALK-Abello A/S, a pharmaceutical company that is a world leader in allergy immunotherapy. Prior to ALK-Abello, he was the Chief Financial Officer of Applus A/S, a market leader in automotive inspection services, and prior to Applus, he held several positions at Christian Hansen Holding A/S, a global leader in pharmaceutical manufacturing and producer of natural ingredients for the food, beverage, dietary supplement and agricultural industries. Mr. Moreno Toscano holds a Master's Degree in Law from the Universidad de Murcia in Spain and an MBA in International Finance and Strategy from the Ecole Nationale des Ponts et Chaussees in Paris. Mr. Moreno Toscano holds the National Association of Corporate Directors NACD Directorship CertificationTM.
Jose AntonioMoreno Toscano自2020年3月18日起担任我们的董事会成员。自2018年4月以来,Moreno Toscano先生一直担任LFB USA Inc.的首席执行官,LFB USA Inc.是LFB Group的美国子公司,LFB Group是一家全球综合生物制药公司,致力于通过重组,血浆衍生和细胞治疗技术开发创新产品。从2017年7月至2018年3月,Moreno Toscano先生担任安全港合规和临床服务总裁,这是一家综合医疗服务提供商,致力于在初级保健办公室提供特种药品和辅助服务。从2016年7月至2018年9月,他还担任董事会成员。从2016年3月至2017年3月,Moreno Toscano先生担任Kompan Inc.的美洲首席执行官,该公司是Kompan A/S的美国子公司,是游乐场设备的全球领导者。从2006年3月到2016年3月,Moreno Toscano先生担任ALK-Abello Inc.的总裁,该公司是ALK-Abello A/S的美国子公司,该公司是一家制药公司,是过敏免疫疗法的全球领导者。任职ALK-Abello公司之前,他曾担任APplus A/S公司(汽车检测服务的市场领导者)的首席财务官,也曾担任Christian Hansen Holding A/S公司(制药制造和食品、饮料天然成分的生产商的全球领导者)的多种职务,膳食补充剂和农业产业。Moreno Toscano先生拥有西班牙穆尔西亚大学的法学硕士学位和巴黎国立庞茨和肖斯学院的国际金融和战略工商管理硕士学位。Moreno Toscano先生拥有全国公司董事协会NACD董事证书。
Jose Antonio Moreno Toscano, has served as a member of our Board since March 18 2020. Since April 2018 Mr. Moreno Toscano has been Chief Executive Officer of LFB USA Inc., the US subsidiary of LFB Group, a global integrated biopharmaceutical company dedicated to developing innovative products through recombinant, plasma derived and cell therapy technology. From July 2017 to March 2018 Mr. Moreno Toscano served as President of Safe Harbor Compliance and Clinical Services, an integrated health care services provider dedicated to providing specialty pharmaceuticals and ancillary services in primary care offices. From July 2016 to September 2018 he also served as a member of the board of directors. From March 2016 to March 2017 Mr. Moreno Toscano served as CEO, Americas, for Kompan Inc., a US subsidiary of Kompan A/S, a world leader in playground equipment. From March 2006 to March 2016 Mr. Moreno Toscano served as President of ALK-Abello Inc., a US subsidiary of ALK-Abello A/S, a pharmaceutical company that is a world leader in allergy immunotherapy. Prior to ALK-Abello, he was the Chief Financial Officer of Applus A/S, a market leader in automotive inspection services, and prior to Applus, he held several positions at Christian Hansen Holding A/S, a global leader in pharmaceutical manufacturing and producer of natural ingredients for the food, beverage, dietary supplement and agricultural industries. Mr. Moreno Toscano holds a Master's Degree in Law from the Universidad de Murcia in Spain and an MBA in International Finance and Strategy from the Ecole Nationale des Ponts et Chaussees in Paris. Mr. Moreno Toscano holds the National Association of Corporate Directors NACD Directorship CertificationTM.
Brent M. Longnecker

Brent M. Longnecker,2007年以来曾是AmREIT董事,目前作为薪酬委员会主席。他还担任医疗服务公司董事和审计和薪酬委员会委员。自2003年以来他生担任Longnecker & Associates的总裁,一家高管薪酬和治理咨询公司。他从1999年6月至2003年担任资源咨询集团的总裁,资源连接公司执行副总裁。他拥有20多年的咨询经验,包括Deloitte & Touche绩效管理和薪酬咨询实践的国家Principal-In-Charge和德勤& 毕马威会计事务所的合伙人。他的咨询经验包括与房地产公司合作,包括上市公司在内的公司治理问题和资产的管理。他拥有工商管理学士学位,休斯顿大学的工商管理硕士学位。


Brent M. Longnecker, has served as a member of our Board since March 18 2020. Since September 2003 Mr. Longnecker has been the Chairman and Chief Executive Officer of Longnecker & Associates, an executive compensation and corporate governance consulting firm. From June 1999 to August 2003 Mr. Longnecker served as President of Resources Consulting Group, and Executive Vice President of Resources Connection. Mr. Longnecker has over 35 years of consulting experience, including as National Principal-In-Charge for the Performance Management and Compensation Consulting Practice of Deloitte & Touche and as partner at KPMG Peat Marwick. Mr. Longnecker has worked with companies globally including the industries of high tech, finance, service, manufacturing and more. He is a Board Fellow with the NACD and is a past board member. Mr. Longnecker holds Bachelor of Business Administration and MBA degrees from the University of Houston. He is a prolific author on the subjects of executive compensation and corporate governance.
Brent M. Longnecker,2007年以来曾是AmREIT董事,目前作为薪酬委员会主席。他还担任医疗服务公司董事和审计和薪酬委员会委员。自2003年以来他生担任Longnecker & Associates的总裁,一家高管薪酬和治理咨询公司。他从1999年6月至2003年担任资源咨询集团的总裁,资源连接公司执行副总裁。他拥有20多年的咨询经验,包括Deloitte & Touche绩效管理和薪酬咨询实践的国家Principal-In-Charge和德勤& 毕马威会计事务所的合伙人。他的咨询经验包括与房地产公司合作,包括上市公司在内的公司治理问题和资产的管理。他拥有工商管理学士学位,休斯顿大学的工商管理硕士学位。
Brent M. Longnecker, has served as a member of our Board since March 18 2020. Since September 2003 Mr. Longnecker has been the Chairman and Chief Executive Officer of Longnecker & Associates, an executive compensation and corporate governance consulting firm. From June 1999 to August 2003 Mr. Longnecker served as President of Resources Consulting Group, and Executive Vice President of Resources Connection. Mr. Longnecker has over 35 years of consulting experience, including as National Principal-In-Charge for the Performance Management and Compensation Consulting Practice of Deloitte & Touche and as partner at KPMG Peat Marwick. Mr. Longnecker has worked with companies globally including the industries of high tech, finance, service, manufacturing and more. He is a Board Fellow with the NACD and is a past board member. Mr. Longnecker holds Bachelor of Business Administration and MBA degrees from the University of Houston. He is a prolific author on the subjects of executive compensation and corporate governance.

高管简历

中英对照 |  中文 |  英文
J. Rodney Varner

J.Rodney Varner是Genprex的联合创始人,自2012年8月以来一直担任我们的首席执行官兼秘书,以及董事会成员和董事会主席。Varner先生还担任我们的总裁,直到2018年4月10日。Varner先生从1991年开始担任律师事务所Wilson&Varner,LLP的合伙人。Varner先生曾在董事会或高级管理层代表营利性和非营利公司处理各种合同,业务,税收和证券事务,包括技术转让,许可,合作和研究协议,临床试验合同,制药和生物制剂制造和工艺开发合同,州和联邦赠款,包括NIH和SBA赠款,公司治理和信托问题以及房地产事务。Varner先生曾担任公司组建,并购,资本筹集,其他业务交易,商业秘密和其他知识产权保护,房地产和商业诉讼的法律顾问。Varner先生是德克萨斯州律师协会(State Bar of Texas)的成员,并已获准在美国第五巡回上诉法院和美国税务法院(United States Tax Court)执业。Varner先生在德州农工大学(Texas A&M University)以优异的成绩获得工商管理学士学位,并在德克萨斯大学法学院(University of Texas School of Law)获得法学博士学位。


J. Rodney Varner, is a co-founder of Genprex and has served as our Chief Executive Officer and Secretary, and as a member of our Board and as Chairman of our Board since August 2012. Mr. Varner also served as our President from August 2012 until April 10 2018. Mr. Varner was again appointed President on August 10 2020 and currently serves as our President. Mr. Varner has served as a partner of the law firm Wilson & Varner, LLP, since 1991. Mr. Varner has more than 35 years of legal experience with large and small law firms, and as outside general counsel of a Nasdaq listed company. Mr. Varner has represented for-profit and non-profit companies at the board or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers, licensing, collaboration and research agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues, and real estate matters. Mr. Varner served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. Mr. Varner is a member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for the Fifth Circuit and the United States Tax Court. Mr. Varner holds a Bachelor of Business Administration degree, with high honors, from Texas A&M University and a JD degree from The University of Texas School of Law.
J.Rodney Varner是Genprex的联合创始人,自2012年8月以来一直担任我们的首席执行官兼秘书,以及董事会成员和董事会主席。Varner先生还担任我们的总裁,直到2018年4月10日。Varner先生从1991年开始担任律师事务所Wilson&Varner,LLP的合伙人。Varner先生曾在董事会或高级管理层代表营利性和非营利公司处理各种合同,业务,税收和证券事务,包括技术转让,许可,合作和研究协议,临床试验合同,制药和生物制剂制造和工艺开发合同,州和联邦赠款,包括NIH和SBA赠款,公司治理和信托问题以及房地产事务。Varner先生曾担任公司组建,并购,资本筹集,其他业务交易,商业秘密和其他知识产权保护,房地产和商业诉讼的法律顾问。Varner先生是德克萨斯州律师协会(State Bar of Texas)的成员,并已获准在美国第五巡回上诉法院和美国税务法院(United States Tax Court)执业。Varner先生在德州农工大学(Texas A&M University)以优异的成绩获得工商管理学士学位,并在德克萨斯大学法学院(University of Texas School of Law)获得法学博士学位。
J. Rodney Varner, is a co-founder of Genprex and has served as our Chief Executive Officer and Secretary, and as a member of our Board and as Chairman of our Board since August 2012. Mr. Varner also served as our President from August 2012 until April 10 2018. Mr. Varner was again appointed President on August 10 2020 and currently serves as our President. Mr. Varner has served as a partner of the law firm Wilson & Varner, LLP, since 1991. Mr. Varner has more than 35 years of legal experience with large and small law firms, and as outside general counsel of a Nasdaq listed company. Mr. Varner has represented for-profit and non-profit companies at the board or senior management levels in a wide variety of contractual, business, tax and securities matters, including technology transfers, licensing, collaboration and research agreements, clinical trial contracts, pharmaceutical and biologics manufacturing and process development contracts, state and federal grants, including NIH and SBA grants, corporate governance and fiduciary issues, and real estate matters. Mr. Varner served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. Mr. Varner is a member of the State Bar of Texas and has been admitted to practice before the United States Court of Appeals for the Fifth Circuit and the United States Tax Court. Mr. Varner holds a Bachelor of Business Administration degree, with high honors, from Texas A&M University and a JD degree from The University of Texas School of Law.
Ryan M. Confer

RyanM.Confer自2016年9月起担任我们的首席财务官。从2013年12月到2016年9月,他曾担任我们的首席运营和财务官,以及我们的业务经理(从2011年6月到2013年12月)。Confer自2009年公司成立起担任多个战略、运营和财务职位,包括Confer Capital,Inc.顾问和员工。Confer先生还曾担任德克萨斯大学奥斯汀分校IC2研究所(University of Texas at Austin’;S IC2Institute)的国际业务开发顾问,在那里他专注于评估国内和国际市场上适用于与该大学相关的技术孵化器计划的新兴技术的商业化潜力。Confer先生拥有宾夕法尼亚布鲁姆斯堡大学(Bloomsburg University of Pennsylvania)的金融和法律研究学士学位,以及得克萨斯大学奥斯汀分校(University of Texas at Austin)麦康姆斯商学院(McCombs School of Business)的技术商业化硕士学位。


Ryan M. Confer, has served as our Chief Financial Officer since September 2016. From December 2013 through September 2016 he served as our Chief Operating and Financial Officer, and from June 2011 to December 2013 as our business Manager. Mr. Confer has served us in a variety of strategic, operations, and finance capacities since our inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr. Confer has over 10 years of entrepreneurial and executive experience in planning, launching, developing, and growing emerging technology companies. He has served in c-level and vice president roles for non-profit and for-profit entities since 2008. Most notably, Mr. Confer served as VP of Customer Experience and then later as VP of Strategy for KaiNexus Inc., an emerging technology company that develops continuous improvement software. Prior to his entrepreneurial experience, Mr. Confer served as a business development consultant for the University of Texas at Austin's IC2 Institute, an international think tank and incubator, where he focused on evaluating the commercialization potential of nascent technologies in emerging growth markets. Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.
RyanM.Confer自2016年9月起担任我们的首席财务官。从2013年12月到2016年9月,他曾担任我们的首席运营和财务官,以及我们的业务经理(从2011年6月到2013年12月)。Confer自2009年公司成立起担任多个战略、运营和财务职位,包括Confer Capital,Inc.顾问和员工。Confer先生还曾担任德克萨斯大学奥斯汀分校IC2研究所(University of Texas at Austin’;S IC2Institute)的国际业务开发顾问,在那里他专注于评估国内和国际市场上适用于与该大学相关的技术孵化器计划的新兴技术的商业化潜力。Confer先生拥有宾夕法尼亚布鲁姆斯堡大学(Bloomsburg University of Pennsylvania)的金融和法律研究学士学位,以及得克萨斯大学奥斯汀分校(University of Texas at Austin)麦康姆斯商学院(McCombs School of Business)的技术商业化硕士学位。
Ryan M. Confer, has served as our Chief Financial Officer since September 2016. From December 2013 through September 2016 he served as our Chief Operating and Financial Officer, and from June 2011 to December 2013 as our business Manager. Mr. Confer has served us in a variety of strategic, operations, and finance capacities since our inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr. Confer has over 10 years of entrepreneurial and executive experience in planning, launching, developing, and growing emerging technology companies. He has served in c-level and vice president roles for non-profit and for-profit entities since 2008. Most notably, Mr. Confer served as VP of Customer Experience and then later as VP of Strategy for KaiNexus Inc., an emerging technology company that develops continuous improvement software. Prior to his entrepreneurial experience, Mr. Confer served as a business development consultant for the University of Texas at Austin's IC2 Institute, an international think tank and incubator, where he focused on evaluating the commercialization potential of nascent technologies in emerging growth markets. Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.
Michael T. Redman

Michael T.Redman自2020年3月12日起担任我们的执行副总裁兼首席运营官。从2019年8月7日至2020年3月12日,Redman先生不时担任我们的顾问。Redman先生在生命科学行业拥有超过30年的经验。他曾担任临床阶段公司的多种关键执行职务,在那里他专注于战略业务开发、美国和全球制造和临床运营。他在生物技术和制药行业的多个战略交易的完善中发挥了重要作用。自2019年6月以来,Redman先生一直担任生物技术和生命科学公司的独立顾问。从2007年1月至2019年5月,Redman先生担任Oncolix,Inc.的总裁,首席执行官兼董事,该公司是一家上市的临床阶段生物制药公司,致力于开发针对妇女和儿童癌症的疗法。从2018年开始,Redman先生还担任Oncolix的首席财务官。任职Oncolix公司期间,他曾推动公司的领先药物进入人类临床试验,完成了一种有前途的用于治疗骨相关癌症的放射性药物的内部许可,并使公司上市。任职Oncolix公司之前,他曾担任Bone Medical Limited公司(澳大利亚临床阶段公司,开发治疗骨质疏松症的口服肽产品)的首席执行官。2001年,他联合创立了Opexa Pharmaceuticals Inc.,这是一家为多种疾病开发免疫疗法的公司,并担任其总裁兼首席执行官直到2005年。Redman先生还在Zonagen,Inc.(现为Repros Therapeutics Inc.)担任重要管理职位,该公司是Allergan plc,Aronex Pharmaceuticals,Inc.(被Antigenics Inc.收购),Biovail Corporation和American Home Products Corporation(更名为Wyeth,被辉瑞公司收购)的一部分。Redman先生获得了密苏里大学的生物学学士学位和菲尼克斯大学的工商管理硕士学位。


Michael T. Redman, has served as our Executive Vice President and Chief Operating Officer since March 12 2020. From time to time from August 7 2019 to March 12 2020 Mr. Redman served as an advisor to us. Mr. Redman has more than 30 years of experience in the life sciences industry. He has held a variety of key executive roles at clinical-stage companies, where he focused on strategic business development and U.S. and worldwide manufacturing and clinical operations. He has been instrumental in the consummation of multiple strategic transactions in the biotechnology and pharmaceutical industries. Since June 2019 Mr. Redman has served as an independent consultant to biotechnology and life science companies. From January 2007 to May 2019 Mr. Redman served as President, Chief Executive Officer and Director of Oncolix, Inc., a publicly traded clinical-stage biopharmaceutical company focused on developing therapies for women's and children's cancers. Beginning in 2018 Mr. Redman also served as the Chief Financial Officer of Oncolix. During his tenure at Oncolix, he advanced the company's lead drug into human clinical trials, completed the in-licensing of a promising radiopharmaceutical drug for the treatment of bone-related cancers, and took the company public. Prior to Oncolix, he was the CEO of Bone Medical Limited, an Australia-based clinical stage company developing oral peptide products for the treatment of osteoporosis. In 2001 he co-founded Opexa Pharmaceuticals Inc., a company developing immunotherapies for a variety of diseases, and served as its President and CEO until 2005. Mr. Redman also held key management positions with Zonagen, Inc. now Repros Therapeutics Inc., which is a part of Allergan plc, Aronex Pharmaceuticals, Inc. (acquired by Antigenics Inc.), Biovail Corporation and American Home Products Corporation (which was renamed Wyeth and acquired by Pfizer Inc.). Mr. Redman earned a BA in Biology from the University of Missouri and an MBA from the University of Phoenix.
Michael T.Redman自2020年3月12日起担任我们的执行副总裁兼首席运营官。从2019年8月7日至2020年3月12日,Redman先生不时担任我们的顾问。Redman先生在生命科学行业拥有超过30年的经验。他曾担任临床阶段公司的多种关键执行职务,在那里他专注于战略业务开发、美国和全球制造和临床运营。他在生物技术和制药行业的多个战略交易的完善中发挥了重要作用。自2019年6月以来,Redman先生一直担任生物技术和生命科学公司的独立顾问。从2007年1月至2019年5月,Redman先生担任Oncolix,Inc.的总裁,首席执行官兼董事,该公司是一家上市的临床阶段生物制药公司,致力于开发针对妇女和儿童癌症的疗法。从2018年开始,Redman先生还担任Oncolix的首席财务官。任职Oncolix公司期间,他曾推动公司的领先药物进入人类临床试验,完成了一种有前途的用于治疗骨相关癌症的放射性药物的内部许可,并使公司上市。任职Oncolix公司之前,他曾担任Bone Medical Limited公司(澳大利亚临床阶段公司,开发治疗骨质疏松症的口服肽产品)的首席执行官。2001年,他联合创立了Opexa Pharmaceuticals Inc.,这是一家为多种疾病开发免疫疗法的公司,并担任其总裁兼首席执行官直到2005年。Redman先生还在Zonagen,Inc.(现为Repros Therapeutics Inc.)担任重要管理职位,该公司是Allergan plc,Aronex Pharmaceuticals,Inc.(被Antigenics Inc.收购),Biovail Corporation和American Home Products Corporation(更名为Wyeth,被辉瑞公司收购)的一部分。Redman先生获得了密苏里大学的生物学学士学位和菲尼克斯大学的工商管理硕士学位。
Michael T. Redman, has served as our Executive Vice President and Chief Operating Officer since March 12 2020. From time to time from August 7 2019 to March 12 2020 Mr. Redman served as an advisor to us. Mr. Redman has more than 30 years of experience in the life sciences industry. He has held a variety of key executive roles at clinical-stage companies, where he focused on strategic business development and U.S. and worldwide manufacturing and clinical operations. He has been instrumental in the consummation of multiple strategic transactions in the biotechnology and pharmaceutical industries. Since June 2019 Mr. Redman has served as an independent consultant to biotechnology and life science companies. From January 2007 to May 2019 Mr. Redman served as President, Chief Executive Officer and Director of Oncolix, Inc., a publicly traded clinical-stage biopharmaceutical company focused on developing therapies for women's and children's cancers. Beginning in 2018 Mr. Redman also served as the Chief Financial Officer of Oncolix. During his tenure at Oncolix, he advanced the company's lead drug into human clinical trials, completed the in-licensing of a promising radiopharmaceutical drug for the treatment of bone-related cancers, and took the company public. Prior to Oncolix, he was the CEO of Bone Medical Limited, an Australia-based clinical stage company developing oral peptide products for the treatment of osteoporosis. In 2001 he co-founded Opexa Pharmaceuticals Inc., a company developing immunotherapies for a variety of diseases, and served as its President and CEO until 2005. Mr. Redman also held key management positions with Zonagen, Inc. now Repros Therapeutics Inc., which is a part of Allergan plc, Aronex Pharmaceuticals, Inc. (acquired by Antigenics Inc.), Biovail Corporation and American Home Products Corporation (which was renamed Wyeth and acquired by Pfizer Inc.). Mr. Redman earned a BA in Biology from the University of Missouri and an MBA from the University of Phoenix.
Catherine M. Vaczy

Catherine M. Vaczy,从2005年起,她担任我公司副总裁、法律顾问和总顾问,并从2014年起,担任公司总顾问。她是高级商业执行和顾问,在生物技术业有20多年的领导经验。从1997至2003年,她在上市公司ImClone Systems Incorporated担任高级职位,该公司开发生物治疗方法以满足癌症患者的医疗需求,并曾担任副总裁。法律顾问和助理总顾问。在ImClone,她作为公司每日运营的重要顾问帮助促进了一系列重要的战略联盟,包括与Erbitux之间10亿美元的共同发展协议,该公司的定向治疗能治疗转移性直肠癌和头颈癌。ImClone于2006年被Eli Lilly and Company收购,纳斯达克股票代码:LLY。从1988年至1996年,她担任公司律师,为纽约律师事务所Ross and Hardies生命科学和技术方面的客户提供意见。她是The Stem for Life Foundation的理事会成员,并监督基金会的学生大使项目。她是纽约The Union League Club的成员及其艺术委员会成员。她在Boston College获得学士学位并在St. John's University School of Law获得法学博士学位。


Catherine M. Vaczy, has served as our as Executive Vice President and Chief Strategy Officer since March 12 2020 and from November 10 2020 as our Executive Vice President, General Counsel and Chief Strategy Officer. From December 1 2019 to March 12 2020 Ms. Vaczy served as an advisor to us. Ms. Vaczy has more than 20 years of experience as a founder and senior executive of life science companies, serving as a strategic partner and business and legal advisor to senior leadership teams and boards. From 2015 through 2019 Ms. Vaczy provided strategic advisory services to early stage biotechnology companies and other technology driven companies. In 2005 Ms. Vaczy co-founded and served for 10 years as General Counsel and Secretary of NeoStem, Inc. now Caladrius Biosciences, Inc., a Nasdaq-listed clinical stage biotechnology company that combined a leading cell and gene therapy process development and manufacturing organization (which was sold to Hitachi Chemical Co. America, Ltd.) with a development pipeline of cell therapy products. Prior to founding NeoStem, from 1997 through 2003 she was an executive serving in roles of increasing responsibility, most recently as Vice President, Legal, Associate General Counsel and Assistant Secretary of Nasdaq-listed ImClone Systems Incorporated (which was sold to Eli Lily and Company), a pioneer in targeted cancer therapy, where she was instrumental in forging important strategic alliances, including a transformative $1 billion co-development deal for the Company's blockbuster drug, Erbitux. Earlier in her career, Ms. Vaczy was a practicing attorney in a nationally recognized law firm representing early-stage life science and other technology companies. Ms. Vaczy received a BA degree from Boston College and a JD degree from St. John's University School of Law.
Catherine M. Vaczy,从2005年起,她担任我公司副总裁、法律顾问和总顾问,并从2014年起,担任公司总顾问。她是高级商业执行和顾问,在生物技术业有20多年的领导经验。从1997至2003年,她在上市公司ImClone Systems Incorporated担任高级职位,该公司开发生物治疗方法以满足癌症患者的医疗需求,并曾担任副总裁。法律顾问和助理总顾问。在ImClone,她作为公司每日运营的重要顾问帮助促进了一系列重要的战略联盟,包括与Erbitux之间10亿美元的共同发展协议,该公司的定向治疗能治疗转移性直肠癌和头颈癌。ImClone于2006年被Eli Lilly and Company收购,纳斯达克股票代码:LLY。从1988年至1996年,她担任公司律师,为纽约律师事务所Ross and Hardies生命科学和技术方面的客户提供意见。她是The Stem for Life Foundation的理事会成员,并监督基金会的学生大使项目。她是纽约The Union League Club的成员及其艺术委员会成员。她在Boston College获得学士学位并在St. John's University School of Law获得法学博士学位。
Catherine M. Vaczy, has served as our as Executive Vice President and Chief Strategy Officer since March 12 2020 and from November 10 2020 as our Executive Vice President, General Counsel and Chief Strategy Officer. From December 1 2019 to March 12 2020 Ms. Vaczy served as an advisor to us. Ms. Vaczy has more than 20 years of experience as a founder and senior executive of life science companies, serving as a strategic partner and business and legal advisor to senior leadership teams and boards. From 2015 through 2019 Ms. Vaczy provided strategic advisory services to early stage biotechnology companies and other technology driven companies. In 2005 Ms. Vaczy co-founded and served for 10 years as General Counsel and Secretary of NeoStem, Inc. now Caladrius Biosciences, Inc., a Nasdaq-listed clinical stage biotechnology company that combined a leading cell and gene therapy process development and manufacturing organization (which was sold to Hitachi Chemical Co. America, Ltd.) with a development pipeline of cell therapy products. Prior to founding NeoStem, from 1997 through 2003 she was an executive serving in roles of increasing responsibility, most recently as Vice President, Legal, Associate General Counsel and Assistant Secretary of Nasdaq-listed ImClone Systems Incorporated (which was sold to Eli Lily and Company), a pioneer in targeted cancer therapy, where she was instrumental in forging important strategic alliances, including a transformative $1 billion co-development deal for the Company's blockbuster drug, Erbitux. Earlier in her career, Ms. Vaczy was a practicing attorney in a nationally recognized law firm representing early-stage life science and other technology companies. Ms. Vaczy received a BA degree from Boston College and a JD degree from St. John's University School of Law.